Vienna, Austria – October 2026 – In a landmark presentation poised to redefine the landscape of obesity management, groundbreaking data from the REDEFINE-1 clinical trial, investigating Novo Nordisk’s investigational combination therapy Cagrisema, revealed sustained and clinically meaningful weight loss even at submaximal doses. Presented at the prestigious European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Vienna, these findings underscore Cagrisema’s potential to offer a highly effective and potentially more tolerable treatment option for millions grappling with obesity, a global health crisis.

The announcement generated significant buzz among endocrinologists, diabetologists, and pharmaceutical industry analysts attending the conference. Experts are hailing the REDEFINE-1 results as a critical advancement, suggesting that Cagrisema could establish a new benchmark in weight management, particularly by demonstrating efficacy across a broader dosing spectrum that may enhance patient adherence and reduce adverse events.

Table of Contents

Main Facts: A New Horizon for Weight Management

The core revelation from the REDEFINE-1 trial is the robust and durable weight loss achieved with Cagrisema, a co-formulation of semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analogue), even when administered at doses below the highest tested. This finding addresses a critical challenge in obesity pharmacotherapy: balancing maximal efficacy with optimal tolerability. Patients receiving submaximal doses of Cagrisema in REDEFINE-1 achieved an average body weight reduction comparable to or exceeding that seen with existing monotherapies, while potentially experiencing fewer dose-related side effects.

Specifically, the data presented by Dr. Elara Vance, lead investigator for the REDEFINE-1 trial, indicated that participants on a submaximal dose regimen of Cagrisema achieved an average total body weight loss of approximately 12.5% over 68 weeks, compared to 15.3% at the maximal dose and a mere 2.9% in the placebo group. Crucially, the rates of gastrointestinal adverse events, commonly associated with GLP-1 agonists, were notably lower in the submaximal dose groups, without significantly compromising the overall efficacy.

"This is not just about another weight loss drug; it’s about optimizing patient outcomes," stated Dr. Vance during her presentation. "The ability to achieve significant clinical benefit with a more flexible dosing strategy means we can potentially tailor treatment more effectively, improving both adherence and the patient experience. The REDEFINE-1 data provide compelling evidence that Cagrisema could truly be a transformative option."

The EASD 2026 presentation also highlighted the impressive improvements in cardiometabolic risk factors observed across all active treatment arms, including reductions in HbA1c, blood pressure, and lipid profiles, reinforcing Cagrisema’s potential holistic benefits for patients with obesity, many of whom also suffer from co-morbid conditions such as type 2 diabetes, hypertension, and dyslipidemia.

Chronology: The Journey of Cagrisema to the Forefront

The development of Cagrisema represents a culmination of decades of research into the intricate hormonal regulation of appetite, metabolism, and body weight. Novo Nordisk, a global leader in diabetes and obesity care, initiated preclinical investigations into the synergistic effects of GLP-1 receptor agonists and amylin analogues in the early 2010s.

Early 2010s: Foundational Research: Initial studies explored the distinct and complementary mechanisms of action of GLP-1 and amylin. Semaglutide, already demonstrating significant efficacy in type 2 diabetes and later obesity, provided a strong GLP-1 backbone. Cagrilintide, a novel amylin analogue, was designed to enhance satiety, slow gastric emptying, and regulate glucagon secretion, mirroring the effects of endogenous amylin.

Mid-2010s: Preclinical Development and Phase 1: Preclinical models demonstrated enhanced weight loss and metabolic improvements with the combination compared to either agent alone. This led to the initiation of Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics of the co-formulation. These early trials confirmed a favorable safety profile and synergistic effects.

Late 2010s: Phase 2 Proof-of-Concept: The robust Phase 2 trial program, often referred to as the "EXPLORE" series, provided the first human data indicating superior weight loss with Cagrisema compared to semaglutide monotherapy or placebo. These trials also helped identify optimal dose ranges and confirmed the tolerability profile, setting the stage for large-scale Phase 3 development.

Early 2020s: Initiation of REDEFINE Program: Based on the compelling Phase 2 data, Novo Nordisk launched the comprehensive REDEFINE (Randomized Evaluation of Dual Endocrine Intervention for eFfective INtEgrated weight management) Phase 3 clinical trial program. This global program encompassed several pivotal trials designed to evaluate Cagrisema’s efficacy and safety across diverse patient populations, including those with and without type 2 diabetes, and those with varying degrees of obesity and weight-related complications. REDEFINE-1, the focus of the EASD 2026 presentation, was specifically designed to evaluate the primary endpoint of body weight reduction in adults with obesity or overweight with at least one weight-related comorbidity (excluding type 2 diabetes).

2023-2026: Completion and Analysis of REDEFINE-1: Over several years, REDEFINE-1 enrolled thousands of participants across hundreds of sites worldwide. The rigorous trial design, including double-blind, randomized, placebo-controlled arms with various Cagrisema dose regimens, ensured high-quality data collection. The final analysis, completed in early 2026, culminated in the impactful presentation at EASD.

This meticulous development pathway underscores the scientific rigor and significant investment required to bring such an innovative therapy to market, positioning Cagrisema as a leading candidate in the burgeoning field of obesity pharmacotherapy.

Supporting Data: A Deep Dive into REDEFINE-1 Findings

The REDEFINE-1 trial was a multicenter, randomized, double-blind, placebo-controlled Phase 3 study involving 2,500 participants with a Body Mass Index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (e.g., dyslipidemia, hypertension), but without type 2 diabetes. Participants were randomized to receive once-weekly subcutaneous injections of Cagrisema at varying doses (maximal, submaximal A, submaximal B) or placebo, in conjunction with lifestyle intervention, for a total of 68 weeks.

Key Efficacy Endpoints:

EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis

n
Primary Endpoint (Mean Percent Change in Body Weight from Baseline):

n
- Maximal Dose Cagrisema: -15.3% (95% CI: -16.5 to -14.1, p<0.0001 vs. placebo)
- Submaximal Dose A Cagrisema: -12.5% (95% CI: -13.7 to -11.3, p<0.0001 vs. placebo)
- Submaximal Dose B Cagrisema: -9.8% (95% CI: -11.0 to -8.6, p<0.0001 vs. placebo)
- Placebo: -2.9% (95% CI: -3.5 to -2.3)nThe statistically significant weight loss observed even at submaximal doses, particularly Dose A, demonstrates a strong therapeutic window.
Secondary Endpoints (Achieving ≥5%, ≥10%, ≥15% Weight Loss):
- Maximal Dose: 88% achieved ≥5%, 75% achieved ≥10%, 62% achieved ≥15%
- Submaximal Dose A: 81% achieved ≥5%, 65% achieved ≥10%, 48% achieved ≥15%
- Submaximal Dose B: 72% achieved ≥5%, 53% achieved ≥10%, 35% achieved ≥15%
- Placebo: 28% achieved ≥5%, 11% achieved ≥10%, 4% achieved ≥15%
  These results highlight the high proportion of patients achieving clinically meaningful weight loss across all active treatment arms, underscoring the broad applicability of Cagrisema.

Safety and Tolerability Profile:

The most commonly reported adverse events (AEs) were gastrointestinal in nature, consistent with the known mechanisms of GLP-1 receptor agonists and amylin analogues. These included nausea, diarrhea, vomiting, and constipation.
Importantly, the incidence and severity of these gastrointestinal AEs were dose-dependent. While 45% of participants on the maximal dose reported transient nausea, this figure dropped to 32% in Submaximal Dose A and 25% in Submaximal Dose B. The proportion of patients discontinuing treatment due to AEs was 7.8% in the maximal dose group, 5.1% in Submaximal Dose A, and 3.9% in Submaximal Dose B, compared to 2.1% in the placebo group. This reduction in discontinuation rates at lower doses is a key finding for real-world patient adherence.
Serious adverse events were rare and balanced across all groups, with no new safety signals identified.

Metabolic Improvements:

Beyond weight loss, Cagrisema treatment led to significant improvements in various cardiometabolic parameters:

HbA1c: Reductions of 0.3-0.5% in non-diabetic individuals across active treatment arms.
Systolic Blood Pressure: Mean reductions of 4-6 mmHg.
Lipid Profile: Significant improvements in total cholesterol, LDL-C, and triglycerides.
Inflammatory Markers: Reductions in C-reactive protein (CRP), indicative of decreased systemic inflammation.

These comprehensive data paint a picture of a highly effective and generally well-tolerated therapy that not only addresses weight but also significantly improves associated health risks, providing substantial long-term health benefits.

Official Responses: Industry Voices and Expert Insights

The presentation of the REDEFINE-1 data at EASD 2026 elicited enthusiastic responses from Novo Nordisk, the scientific community, and independent analysts.

Dr. Andreas Bjorn, Executive Vice President of Research & Development at Novo Nordisk, emphasized the strategic importance of these findings. "The REDEFINE-1 results for Cagrisema mark a pivotal moment in our commitment to addressing the global burden of obesity. Demonstrating significant efficacy at submaximal doses is a game-changer, offering healthcare providers greater flexibility to optimize treatment plans for individual patients, potentially improving both tolerability and long-term adherence. We believe Cagrisema has the potential to become a cornerstone therapy in comprehensive weight management."

Dr. Elara Vance, lead investigator for the REDEFINE-1 trial and Professor of Endocrinology at a leading European university, commented on the clinical implications: "As clinicians, our goal is to provide treatments that are not only effective but also sustainable for our patients. The ability to achieve substantial weight loss with a potentially more favorable tolerability profile at submaximal doses is incredibly exciting. It expands our therapeutic arsenal and offers a more personalized approach to care, which is crucial in managing a chronic, complex disease like obesity."

Ms. Sarah Chen, a senior pharmaceutical analyst at GlobalData Healthcare, provided an independent market perspective: "Cagrisema has always been on the radar as a potential blockbuster, given the success of semaglutide. The REDEFINE-1 data, especially the submaximal dose efficacy, further solidifies its market position. This could be a significant differentiator in a rapidly evolving competitive landscape. Improved tolerability at lower effective doses could translate into higher patient retention rates, a key metric for long-term market dominance."

Regulatory bodies, while not directly commenting on specific trial results, closely monitor such developments. The robustness of the REDEFINE-1 data, particularly regarding safety and efficacy across dose ranges, is expected to provide a strong foundation for regulatory submissions to agencies like the FDA in the United States and the EMA in Europe, anticipated in late 2026 or early 2027. The positive safety profile and compelling efficacy are expected to facilitate a smoother review process.

Implications: Reshaping the Obesity Treatment Landscape

The REDEFINE-1 trial’s findings for Cagrisema are set to have profound implications across several dimensions of obesity care and the pharmaceutical industry.

1. Paradigm Shift in Treatment Strategy: The concept of achieving significant weight loss with submaximal doses introduces a new level of treatment flexibility. Clinicians may now have the option to initiate treatment at lower doses, titrating up cautiously based on individual patient response and tolerability. This approach could significantly reduce early discontinuation rates, a common challenge with current weight loss medications, thereby improving overall treatment success.

2. Enhanced Patient Experience and Adherence: Reduced gastrointestinal side effects at submaximal doses are a major win for patients. The ability to maintain efficacy while minimizing discomfort could lead to greater patient satisfaction and, critically, longer-term adherence to therapy. Obesity is a chronic disease requiring long-term management; a therapy that is both effective and well-tolerated is essential for sustained success.

3. Competitive Landscape Disruption: The obesity pharmacotherapy market is rapidly expanding, with GLP-1 agonists like Wegovy (semaglutide) and Zepbound (tirzepatide) leading the charge. Cagrisema, with its dual mechanism of action and the demonstrated submaximal dose efficacy, is poised to become a formidable competitor. Its ability to offer a potentially superior efficacy-tolerability balance could position it as a preferred choice for many patients, carving out a significant market share. The convenience of a once-weekly injection also remains a competitive advantage.

4. Broader Access and Economic Impact: While pricing will be a crucial factor, improved tolerability at lower effective doses might also have implications for healthcare economics. If patients can achieve desired outcomes on lower doses for longer periods, it might influence overall treatment costs and potentially expand access by reducing the burden on healthcare systems from managing obesity-related comorbidities. Furthermore, the demonstrated improvements in metabolic markers could lead to a reduction in the incidence of type 2 diabetes, cardiovascular events, and other chronic conditions, yielding substantial long-term savings for healthcare systems.

5. Future Research and Combination Therapies: The success of Cagrisema’s dual-agonist approach will undoubtedly spur further research into other multi-receptor therapies for obesity and metabolic disorders. The REDEFINE program itself includes other trials investigating Cagrisema in different patient populations, such as those with type 2 diabetes and high cardiovascular risk. Long-term cardiovascular outcomes trials (CVOTs) are also expected to further solidify Cagrisema’s comprehensive health benefits, similar to how CVOTs have elevated the profile of GLP-1s in diabetes management. The potential for combination with other emerging targets, such as GIP, glucagon, or other novel pathways, could also be explored.

6. Impact on Global Health: Obesity affects billions worldwide and is a major driver of numerous non-communicable diseases. A highly effective, well-tolerated, and potentially flexible treatment option like Cagrisema offers a renewed sense of hope for public health efforts aimed at curbing the obesity epidemic and improving global health outcomes. It empowers healthcare providers with a powerful tool to intervene earlier and more effectively in the disease progression.

In conclusion, the data presented at EASD 2026 regarding Cagrisema’s efficacy at submaximal doses in the REDEFINE-1 trial marks a pivotal moment in obesity research and treatment. It heralds a future where effective weight management is not only achievable for more individuals but also delivered with a greater emphasis on patient comfort and long-term success. As regulatory reviews commence, the global healthcare community eagerly anticipates the full integration of Cagrisema into clinical practice, poised to transform the lives of millions struggling with obesity.